At present, the company has more than 400 employees, including more than 250 R&D and technical personnel. Laimei Pharmaceutical has outstanding innovation ability, solid technical foundation, rich industrialization experience and strong marketing network. It is one of the earliest enterprises that passed GMP and GSP certification in China, and the number of new drug applications is among the best in Chongqing.
In order to improve Laimei's existing level and industrial scale, enhance its core competitiveness, further consolidate Laimei's competitive position in the industry, enhance cohesion and attractiveness, and operate more healthily and standardly, Laimei will strive to land in the domestic securities market as soon as possible.
The company was listed on Shenzhen Growth Enterprise Market on October 30, 2009 with the stock code of 300006.